89Bio Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Okay, great. Good morning, everybody. For our next presentation. I'm joined by Rohan Palekar, the CEO of 89bio. Welcome to our conference.
Thanks Kristen. [Great to be here.]
Questions & Answers
Awesome. So the last 12 months have been one of the most exciting times for investors focusing on the NASH space. We went from seeing a few disappointing trial results to now having a few positive ones, yourself included. And are one step closer towards a first potential approval. So why do you think now more than ever investors should focus their time on this space?
Kristen, (technical difficulty) the last 12 months, I think at NASH has been pretty transformational, had a little time period where you had a bunch of trial results which came out negative. And then in the last 12 months, including
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |